Biological basis and clinical study of glycogen synthase kinase- 3β-targeted therapy by drug repositioning for glioblastoma

BACKGROUND: Glycogen synthase kinase (GSK)-3β has emerged as an appealing therapeutic target for glioblastoma (GBM). Here, we investigated the therapeutic effect of the current approved drugs against GBM via inhibition of GSK3β activity both, in experimental setting and in a clinical study for recur...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Furuta, Takuya, Sabit, Hemragul, Dong, Yu, Miyashita, Katsuyoshi, Kinoshita, Masashi, Uchiyama, Naoyuki, Hayashi, Yasuhiko, Hayashi, Yutaka, Minamoto, Toshinari, Nakada, Mitsutoshi
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2017
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5410264/
https://ncbi.nlm.nih.gov/pubmed/28423558
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.15206
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados